On Cell & Gene: The Podcast, Amit Kumar, Ph.D., CEO, at Anixa Biosciences, details the progress on their Phase 1 trial for ovarian cancer and why the company’s ovarian cancer program is integral for initial proof of concept for other solid tumor indications. Dr. Kumar covers why CAR-T therapy uses an existing hormone/hormone receptor relationship to create a targeted approach to treat ovarian cancer. Listen now and subscribe so you never miss an episode!
Throughout the pandemic, the FDA has demonstrated more than ever the value of using a risk-based approach to inspectional activities, which must be embraced and mirrored in industry when it comes to supplier and vendor audits, especially by early-stage pharmaceutical companies.
Did you know about the alternative rapid method for in vivo MAP/HAP/RAP testing? Download our tech note Blazar Platform: Rodent Virus Panel From The BioReliance Portfolio to learn more about our novel degenerate PCR assay designed for the detection of a broad range of adventitious agents.